phospho-GSK3 Alpha + Beta (Tyr279+Tyr216)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 2073R
英文名称phospho-GSK3 Alpha + Beta (Tyr279+Tyr216)
中文名称磷酸化糖原合酶激酶3α/β抗体
别 名GSK3B(Phospho-Tyr279+Tyr216); GSK3B(Phospho-Y279/Y216); p-GSK-3 Beta(Tyr279+Tyr216); p-GSK-3 beta(Y279/Y216); Glycogen synthase kinase 3 beta; GSK 3 beta; GSK 3B; GSK3B; GSK3B protein; GSK3beta isoform; GSK3 beta; Glycogen synthase kinase-3 beta; GSK-3 beta; GSK3B_HUMAN. GSK 3β; GSK 3 β; GSK-3β; GSK3β; GSK 3α; GSK 3 α; GSK-3α; GSK3α;
JournalPMIDIFApplicationBehavioural Brain Research (2012)232199643.3270IHC-P/WB
说 明 书100ul
产品类型磷酸化抗体
研究领域细胞生物 **学 神经生物学 信号转导 细胞凋亡 转录调节因子 激酶和磷酸酶
抗体来源Rabbit
克隆类型Polyclonal
phospho-GSK3 Alpha + Beta (Tyr279+Tyr216)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep, Guinea Pig,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg /test IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量47/51kDa
细胞定位细胞核 细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human GSK3 Alpha/Beta around the phosphorylation site of Tyr279/Tyr216:VS(p-Y)IC
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-GSK3 Alpha + Beta (Tyr279+Tyr216)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
Glycogen synthase kinase 3 (GSK3) is a proline directed serine threonine kinase that was initially identified as a phosphorylating and inactivating glycogen synthase, a key enzyme in glycogen metabolism. Since then, it has been shown to be involved in the regulation of a diverse array of cellular functions, including protein synthesis, cell proliferation, cell differentiation, microtubule assembly/disassembly, and apoptosis. GSK3s substrate specificity is unique in that phosphorylation of substrate only occurs if a phosphoserine or phosphotyrosine is present four residues C terminal to the site of GSK phosphorylation. There exists two isoforms of GSK3, alpha and beta, and they show a high degree of amino acid homology. The two isoforms of GSK3 are strictly regulated via phosphorylation. Phosphorylation of GSK3 beta on Ser9 (Ser21 in GSK3 alpha) by protein kinase B (PKB) causes its inactivation is the primary mechanism responsible for growth factor inhibition of this kinase. Activation of GSK3 beta is dependent upon the phosphorylation of Tyr216 (Tyr279 in GSK3 alpha). Upon activation, it has been shown to phosphorylate a number of different cellular proteins, including p53, c-Myc, c-Jun, heat shock factor 1 (HSF1), and cyclin D1. GSK3 beta also has been shown to phosphorylate aberrant sites on the microtubule associated protein tau, which is critical for the progression of Alzheimer's disease. GSK3B is involved in energy metabolism, neuronal cell development, and body pattern formation.
Function:
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity.
Subunit:
Monomer. Interacts with ARRB2 and DISC1. Interacts with CABYR, MMP2, MUC1, NIN and PRUNE Interacts with AXIN1; the interaction mediates hyperphosphorylation of CTNNB1 leading to its ubiquitination and destruction. Interacts with and phosphorylates SNAI1. Interacts with DNM1L (via a C-terminal domain). Found in a complex composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B.
Subcellular Location:
Cytoplasm. Nucleus. Cell membrane. Note=The phosphorylated form shows localization to cytoplasm and cell membrane. The MEMO1-RHOA-DIAPH1 signaling pathway controls localization of the phosophorylated form to the cell membrane.
Tissue Specificity:
Expressed in testis, thymus, prostate and ovary and weakly expressed in lung, brain and kidney.
Post-translational modifications:
Phosphorylated by AKT1 and ILK1. Upon insulin-mediated signaling, the activated PKB/AKT1 protein kinase phosphorylates and desactivates GSK3B, resulting in the dephosphorylation and activation of GYS1. Activated by phosphorylation at Tyr-216.
Similarity:
Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. GSK-3 subfamily.
Contains 1 protein kinase domain.
SWISS:
P49840
Gene ID:
2932
phospho-GSK3 Alpha + Beta (Tyr279+Tyr216)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-GSK3 Alpha + Beta (Tyr279+Tyr216)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 MCART1 MCART1蛋白抗体
合格 PRSS56 丝氨酸蛋白酶56抗体
合格 Amphiphysin 神经元突触前膜蛋白抗体
合格 ABP 雄**结合蛋白抗体
合格 PRS45 丝氨酸蛋白酶45抗体
合格 PRSS55 丝氨酸蛋白酶55抗体
合格 PAX7 配对盒基因7抗体
合格 NKG2C NK细胞受体2C抗体
合格 CD158e NK细胞抑制性受体3DL1抗体
合格 DLK1 穿膜蛋白DLK1抗体
合格 KCNH1 钾离子通道蛋白EAG1抗体
合格 Glypican 1 磷脂酰基醇蛋白聚糖1抗体
合格 IL-9 白介素9抗体
合格 合格 Apelin Receptor 血管紧张素II受体样蛋白1抗体
合格 BAFF TNF家族B细胞激活因子抗体
合格 ATP4B 氢钾ATP酶通道蛋白抗体
合格 合格 ATP5A ATP5A抗体
合格 Kir6.2 ATP敏感性钾通道亚基kir6.2抗体
合格 合格 TWIST TWIST蛋白抗体
合格 CYP21A2 胆固醇21-羟化酶抗体
合格 Aurora B 有丝分裂激酶B抗体
合格 Nuclear Matrix Protein p84 核基质p84蛋白抗体
合格 CCL19 巨噬细胞炎性蛋白19抗体
合格 IL-4R 白细胞介素4受体抗体
合格 合格 IL-13Ra2 白细胞介素13受体a2抗体
合格 合格 PERK 蛋白激酶样内质网激酶抗体
合格 ICOS ligand 诱导协同刺激分子配体CD275抗体
合格 CD93 CD93抗体
合格 CCL4 巨噬细胞炎性蛋白1β抗体
合格 Macrophage Inflammatory Protein 1 gamma 巨噬细胞炎症蛋白-1γ抗体
合格 MIP3/CCL23 巨噬细胞炎性蛋白抗体